A Prospective Clinical Study to Evaluate the Effectiveness and Safety of Xcell Amnio MatrixTM (XAM) in the Management of Chronic Non-healing DFUs

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

108 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-08-15

Study Completion Date

2026-08-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to evaluate the clinical outcomes of Diabetic Foot Ulcers (DFUs) treated with a weekly application of Xcell Amnio MatrixTM (XAM) as adjunct to standard of care (SOC) compared to SOC alone in male and female over the age of 18 years old. The main question it aims to answer is:

What percentage of wound area will change during the 12 weeks of the treatment phase?

Participants:

* Will be screened and re-screened after 2 weeks to be assessed whether they meet the eligibility criteria
* Eligible subjects will receive study product application, and for 12 weeks will return to the clinic once every 7 days (±3 days) for treatment visits
* Subjects who complete the treatment will be followed up after 2 weeks

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Amnio-Maxx on the Healing Rate of Chronic Diabetic Foot Ulcers.

NCT07209475

Diabetic Foot Ulcer (DFU) Amnio-Maxx

RECRUITING PHASE4

A Modified Platform Trial of Multiple CAMPs for the Management of Diabetic Foot Ulcers and Venous Leg Ulcers

NCT06453187

Diabetic Foot Ulcer Venous Leg Ulcer

RECRUITING NA

Dehydrated Human Amnion Membrane and Standard of Care Versus Standard of Care Alone in Nonhealing Diabetic Foot Ulcers

NCT06550596

Diabetic Foot Ulcer Foot Foot Ulcer +1 more

RECRUITING NA

Clinical Trial Assessing Human Placental Membrane Products and Standard of Care Versus Standard of Care in Nonhealing DFUs and VLUs

NCT06674980

Pathologic Processes Diabetes Mellitus Glucose Metabolism Disorders +16 more

RECRUITING NA

Non-healing Diabetic Foot Ulcers Treated With Standard Care With or Without BR-AM

NCT06565156

Non-infected Diabetic Foot Ulcer Diabetic Foot Diabetic Wound +2 more

ACTIVE_NOT_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetic Foot Ulcer (DFU)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Xcell Amnio MatrixTM (XAM) + Standard of Care (SOC)

Group Type EXPERIMENTAL

Xcell Amnio Matrix

Intervention Type BIOLOGICAL

A lyophilized amniotic membrane allograft

Standard of Care (SOC)

Group Type ACTIVE_COMPARATOR

Standard of Care (SOC)

Intervention Type DRUG

The SOC will be based on investigator's choice

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Xcell Amnio Matrix

A lyophilized amniotic membrane allograft

Intervention Type BIOLOGICAL

Standard of Care (SOC)

The SOC will be based on investigator's choice

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Subjects will be eligible for enrollment in the study only if they meet ALL the following criteria at time of Screening:

1. Subject is 18 years of age or older.
2. Subject has diabetes mellitus (Type 1 or Type 2), requiring insulin or oral/injectable medications to control blood glucose levels
3. Glycosylated hemoglobin (HbA1c) level is \<12%

Note: Prior documented HbA1c within 12 weeks of Screening is acceptable.
4. Duration of ulcer is ≥ 4 weeks but ≤ 1 year, unresponsive to SOC
5. Ulcer area is ≥ 1.5cm2 and ≤ 20cm2 and with a clean, granulating base with minimal adherent slough at the Baseline Visit
6. Ulcer location is at or below the ankle (malleolus)
7. Subject is amenable to use of off-loading, as needed for planter ulcer
8. Ulcer extends through the full thickness of the skin but not down to muscle, tendon, or bone
9. Subject is at least 12 weeks post lower extremity revascularization procedure, if one has been performed.
10. Subject is in general good health, with no clinically significant medical conditions or abnormalities that, in the opinion of the Investigator, would interfere with study participation, the assessment of study endpoints, or pose additional risk to the subject.
11. Adequate circulation to the affected lower extremities as demonstrated by one of the following within 12 weeks of screening:

1. Dorsum transcutaneous oxygen measurement (TCOM) ≥ 30 mmHg,
2. Skin perfusion pressure (SPP) measurement ≥ 30 mmHg,
3. Ankle-Brachial Index (ABI) ≥0.7 and ≤1.2, OR
4. Toe-Brachial Index (TBI) ≥ 0.6
12. Subject is willing to use an acceptable method of contraception throughout the duration of the trial, if of childbearing potential.

Acceptable methods of contraception include abstinence, female subject/partner's use of hormonal contraceptive (oral, patch, injectable, depot or vaginal) in conjunction with a barrier method (e.g., diaphragm, cervical cap, condom, spermicide or sponge), or female subject/partner's use of an implantable device (implantable rod or intrauterine device).

Female subject/partners of non-childbearing potential are defined as surgically sterile (e.g., bilateral tubal ligation, hysterectomy) or two years postmenopausal at time of screening.

All male subjects (excluding men who have been sterilized) with female partners of child-bearing potential must agree to consistently and correctly use a condom for the duration of the study. In addition, subjects may not donate sperm for the same time period.
13. Subject is able to read, understand and sign the informed consent form (ICF).
14. Subject is available and willing to complete all study assessments and can comply with standard of care (debridement, dressing changes etc.) as applicable.

Exclusion Criteria

Subjects meeting ANY of the following criteria at time of Screening will be excluded from enrollment:

1. Clinical evidence of ongoing infection and/or receipt of IV, oral, or topical antimicrobials.
2. Wheelchair bound or bed-ridden (ambulatory with assistance is acceptable).
3. Ulceration at the site of amputation.
4. Undergoing renal dialysis.
5. Known or suspected malignancy in the target ulcer, or a history of cancer in the preceding 5 years (other than carcinoma in situ of the cervix or adequately treated non-melanoma skin cancer).
6. Documented history of osteomyelitis at the target ulcer location within 6 months of screening.
7. History of radiation at the ulcer site.
8. New York Heart Association Class III or IV congestive heart failure or uncontrolled cardiac dysrhythmia.
9. Diagnosis of autoimmune disease(s) (rheumatoid arthritis, lupus, psoriasis, Sjogren's syndrome) or arthritis requiring corticosteroid treatment.
10. Subject has received in the past 4 weeks or is scheduled to receive any of following medication or therapies during the course of the study:

1. Immunosuppressants (including chronic systemic corticosteroids or application of topical steroids to the ulcer surface)
2. Cytotoxic chemotherapy
3. Growth hormone
4. Oral or systemic antifungal or antituberculosis treatment
5. Use of any investigational drug(s) or therapeutic device(s)
11. Target ulcer(s) previously treated with negative pressure, hyperbaric oxygen, or tissue engineered materials (e.g., Apligraf®, EpiFix® or Dermagraft®) or other scaffold materials (e.g., Oasis, Matristem) within 4 weeks prior to screening.
12. Target ulcer(s) anticipated to require negative pressure wound therapy or hyperbaric oxygen at any time during the study.
13. Healing of target ulcer is observed to be ≥35% at the end of the Run-in Period (between Screening and Baseline Visits)
14. Subject is pregnant or breastfeeding.
15. Presence of any other condition(s) which seriously compromises the subject's ability to complete this study or has a known history of poor adherence with medical treatment.
16. Active Charcot foot (stable chronic Charcot foot is not exclusionary).
17. Ulcers on toes 2, 3, 4, and/or 5 only (ulcer on plantar surface of the great toe only is not exclusionary).

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No